Edwards Lifesciences: Driving Growth in Structural Heart Therapies at J.P. Morgan Healthcare Conference

Edwards Lifesciences (NYSE: EW), a global leader in structural heart innovation, is set to present at the 43rd Annual J.P. Morgan Healthcare Conference on Tuesday, January 14, 2025. The company's CEO, Bernard Zovighian, will present at 11:15 a.m. PT, accompanied by CFO Scott Ullem. A live webcast of the presentation will be available on the company's investor relations website at , with an archived version accessible later the same day.

Edwards Lifesciences focuses on developing breakthrough technologies and maintaining partnerships with healthcare stakeholders to deliver life-changing innovations to patients in need. The company's presentation at the J.P. Morgan Healthcare Conference will highlight several key growth drivers and strategic initiatives for 2025.



One of the primary growth drivers for Edwards Lifesciences is its Transcatheter Aortic Valve Replacement (TAVR) segment. The company projects TAVR sales of $4.1 to $4.4 billion in 2025, with constant currency growth of 5% to 7%. This growth is driven by the leading technology of the SAPIEN platform and the expected mid-year indication approval from EARLY TAVR, a pivotal trial studying the treatment of patients with severe aortic stenosis without symptoms. Edwards also anticipates strong global adoption of the SAPIEN 3 Ultra RESILIA system, further boosting TAVR sales.

Another key growth driver is the Transcatheter Mitral and Tricuspid Therapies (TMTT) segment. Edwards projects TMTT sales of $500 to $530 million in 2025, representing constant currency growth of 50% to 60%. This growth is fueled by the commercialization of PASCAL, EVOQUE, and the anticipated CE Mark approval for SAPIEN M3 in mid-2025 and U.S. approval by the first half of 2026. Edwards aims to increase the contribution from an expanding set of structural heart therapies in 2026 and beyond, targeting 10% average annual total company sales growth and double-digit EPS growth.



Edwards Lifesciences also plans to increase its contribution from new therapeutic areas, including Structural Heart Failure and Aortic Regurgitation (AR), to drive future growth. These areas present opportunities to address two new significant patient populations, but also come with challenges such as the need for robust clinical evidence to support approvals and adoption, as well as the requirement for comprehensive support to ensure excellent real-world patient outcomes.

In conclusion, Edwards Lifesciences' presentation at the 43rd Annual J.P. Morgan Healthcare Conference will provide valuable insights into the company's strategic initiatives and growth prospects for 2025 and beyond. With a focus on driving growth in its TAVR and TMTT segments, as well as expanding into new therapeutic areas, Edwards Lifesciences is well-positioned to continue delivering life-changing innovations to patients and generating value for shareholders.